{"id":"W2756647112","doi":"10.1158/1535-7163.mct-17-0456","title":"Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":234,"is_retracted":false,"has_abstract":true,"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"MAPK/ERK pathway; Medicine; In vivo; Melanoma; Cancer research; Cancer; Pharmacology; Phosphorylation; Potency; MEK inhibitor; Targeted therapy; In vitro; Internal medicine; Biology; Cell biology; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003809346,0.0009435361,0.0005305328,0.0003338178,0.0002304177,0.000472496,0.0003602382,0.000418397,0.00117547],"category_scores_gemma":[0.0001047467,0.000246134,0.0004222299,0.0002185817,0.0001875421,0.0002900629,0.0001424285,0.0008760564,0.0004196633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005634564,"about_ca_system_score_gemma":0.0005332657,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00131785,"about_ca_topic_score_gemma":0.002828817,"domain_scores_codex":[0.9998984,0.00001887553,0.000006659739,0.00001272538,0.00002175069,0.00004157152],"domain_scores_gemma":[0.9999497,0.000005955533,0.00001125202,0.000004727593,0.000008839031,0.00001960658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001978889,0.002121808,0.0005057161,0.0002579084,0.00006229045,0.0001598927,0.00004457552,0.001851335,0.9625018,0.0002806661,0.001293617,0.02894153],"study_design_scores_gemma":[0.001908473,0.03007114,0.006105844,0.00004141395,0.0001810784,0.001200452,0.00003933995,0.006343484,0.9449828,0.0001653803,0.008926813,0.00003382433],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781169,0.009662995,0.004249087,0.0006553855,0.0001017022,0.0003848189,0.001237345,0.0004867751,0.00510507],"genre_scores_gemma":[0.9880355,0.0053371,0.002566573,0.0001176595,0.00002484969,0.0001566393,0.001264068,0.00003322717,0.002464413],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00131785,"threshold_uncertainty_score":0.004088163,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03944351150700175,"score_gpt":0.3106321426094479,"score_spread":0.2711886311024461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}